louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03579992: Myoelectric Computer Interface to Reduce Muscle Co-activation After Stroke
Official title: Myoelectric Computer Interface to Reduce Muscle Co-activation After Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2018-07-09
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study examines whether in-lab training with a myoelectric-computer interface (MyCI) can reduce abnormal muscle co-activation after stroke.


Eligibility criteria: Inclusion Criteria:

* Stroke survivors at least 6 months after stroke onset
* Persistent moderate to severe arm impairment
* Increased arm tone

Exclusion Criteria:

* Substantial impairment of vision, memory, language or concentration
* Botulinum toxin use in the affected arm
* Concomitant participation in another research study on the arm

Primary outcomes:
measure: Fugl-Meyer Assessment - Upper Extremity
timeFrame: 6 weeks
Secondary outcomes:
measure: Fugl-Meyer Assessment - Upper Extremity
timeFrame: 10 weeks
measure: Wolf Motor Function Test
timeFrame: 6 and 10 weeks
measure: Motor Activity Log
timeFrame: 6 and 10 weeks
Other outcomes:
measure: Modified Ashworth Scale
timeFrame: 6 and 10 weeks
Locations:
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
Study officials:
affiliation: Northwestern University
name: Marc Slutzky, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mugler EM, Tomic G, Singh A, Hameed S, Lindberg EW, Gaide J, Alqadi M, Robinson E, Dalzotto K, Limoli C, Jacobson T, Lee J, Slutzky MW. Myoelectric Computer Interface Training for Reducing Co-Activation and Enhancing Arm Movement in Chronic Stroke Survivors: A Randomized Trial. Neurorehabil Neural Repair. 2019 Apr;33(4):284-295. doi: 10.1177/1545968319834903. Epub 2019 Mar 19.
citation: Seo G, Kishta A, Mugler E, Slutzky MW, Roh J. Myoelectric interface training enables targeted reduction in abnormal muscle co-activation. J Neuroeng Rehabil. 2022 Jul 1;19(1):67. doi: 10.1186/s12984-022-01045-z.
Clinical trial NCT02796092: Fibered Platinum Coils vs Vascular Plugs in Pelvic Varices Embolization for the Treatment of Pelvic Congestion Syndrome
Official title: Fibered Platinum Coils vs Vascular Plugs in Pelvic Varices Embolization for the Treatment of Pelvic Congestion Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pelvic Congestion Syndrome
Keywords: Pelvic Congestion Syndrome
Pelvic Venous Insufficiency
Chronic pelvic pain
Lead sponsor: Group of Research in Minimally Invasive Techniques
Sponsor class: OTHER
First posted: 2016-06-10
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This prospective randomized study compares the safety and efficacy of two different embolizing agents for the treatment of pelvic congestion syndrome: fibered platinum coils and vascular plugs.

Detailed description: This prospective randomized study compares the safety and efficacy of two embolizing agents for the treatment of pelvic congestion syndrome: fibered platinum coils (Nester coils; Cook Medical) and vascular plugs (Amplatzer vascular plugs II; St. Jude Medical).

Eligibility criteria: Inclusion Criteria:

* Signed informed consent
* Presence of chronic abdominal or pelvic pain for more than 6 months
* \>6 mm pelvic venous caliber measured by transvaginal US
* Presence of venous reflux OR presence of communicating veins assessed by transvaginal Doppler US

Exclusion Criteria:

* Diagnosed gynecological or pelvic pathology: endometriosis, pelvic inflammatory disease, postoperative adhesions, adenomyosis or leiomyoma
* Glomerular filtration rate \<60 ml/min
* History of contrast reaction
* Patients not able to be followed up for at least one year

Primary outcomes:
measure: Change in Pain Scale
timeFrame: 12 months
Secondary outcomes:
measure: Improvement of Dyspareunia
timeFrame: 12 months
measure: Improvement of Urinary Urgency
timeFrame: 12 months
measure: Improvement of Dysmenorrhea
timeFrame: 12 months
measure: Satisfaction With the Procedure
timeFrame: 12 months
measure: Number of Devices Used
timeFrame: intraoperative
measure: Cost of Treatment
timeFrame: Intraoperative
measure: Total Intervention Duration
timeFrame: Intraoperative
measure: Fluoroscopy Time
timeFrame: Intraoperative
measure: Procedure Radiation Dose (DAP)
timeFrame: Intraoperative
measure: Procedure Radiation Dose (AK)
timeFrame: Intraoperative
measure: Complications
timeFrame: intraoperative
measure: Complications
timeFrame: 12 months
measure: Need for Re-embolization
timeFrame: 12 months
Other outcomes:
Locations:
city: Zaragoza
country: Spain
facility: Lozano Blesa University Hospital
Study officials:
affiliation: Universidad de Zaragoza
name: Miguel A De Gregorio, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00986492: Effects of Sleep Deprivation on Food Intake and Motor Activity in Man
Official title: Influence de la Privation Aigue de Sommeil Sur la Prise Alimentaire et l'activité Physique Chez l'Homme
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Sleep deprivation
Food intake
Motor activity
Normal, healthy subjects
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
Collaborators: name: Centre Hospitalier Universitaire Dijon
First posted: 2009-09-30
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy normal subjects

Brief summary: Evidence that shortened period of sleep could be a risk factor for weight gain and obesity has grown over the past decade. Concurrent with the obesity epidemic, numerous studies have reported a parallel epidemic of chronic sleep deprivation. Sleep is important in maintaining energy balance (i.e. acute sleep deprivation impact the normal secretion of ghrelin and decreases leptin plasma levels). Surprisingly, in humans, there is no direct evidence that a shortened night has direct effect on energy metabolism during the following day.

This study is set up to determine whether a partial sleep deprivation night has an impact on appetite and food energy intake and, concomitantly, on physical activity, during the following day.


Eligibility criteria: Inclusion Criteria:

* male
* age between 18 and 30
* healthy
* non smoker
* less than 5 hour of sport per week
* BMI between 20 and 25 kg/m/m

Exclusion Criteria:

* eating disorders,
* dieting or fasting
* restrained (score \>9), disinhibited (score \>11) or hungry subjects (score \>9), according to the Three-Factor Eating Questionnaire general healthiness,
* food-snacking (more than twice a day),

Primary outcomes:
measure: Daily food intake
timeFrame: 24h
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Caen
name: Pierre Denise, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Brondel L, Romer MA, Nougues PM, Touyarou P, Davenne D. Acute partial sleep deprivation increases food intake in healthy men. Am J Clin Nutr. 2010 Jun;91(6):1550-9. doi: 10.3945/ajcn.2009.28523. Epub 2010 Mar 31.
Clinical trial NCT00212992: Biphasic Defibrillation Study: Trial to Compare Fixed Versus Escalating Energy
Official title: A Pilot Randomized Controlled Trial to Compare Fixed Versus Escalating Energy Regimens for Biphasic Waveform Defibrillation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Cardiac Arrest
Keywords: defibrillation
ventricular fibrillation
heart arrest
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2005-09-21
Enrollment: 221
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will compare the effect of constant low-level energy \[150 joules\] to an escalating energy \[200-300-360 joules\] regimen of biphasic waveform defibrillation on multiple patient outcomes.

Detailed description: This pilot, which will enroll 200 subjects, will allow a reasonable estimate of effect size and this will, in turn, allow for the accurate design and planning of a definitive randomized controlled trial. The following outcomes will be evaluated:

1. Important Clinical Outcomes:

   * Successful conversion,
   * Resuscitation to one hour,
   * Survival to hospital discharge,
   * Neurological function, and
   * Quality of life.
2. Process Outcomes:

   * Number of shocks required,
   * Recurrences of VF, and
   * Responsiveness to varying periods of pulselessness.
3. Adverse Outcomes:

   * Myocardial damage.

Eligibility criteria: Inclusion Criteria:

* Witnessed cardiac arrest out-of-hospital requiring defibrillation and given by first responder using an automated external defibrillator

Exclusion Criteria:

* Terminal illness or do-not-resuscitate (DNR) status
* No cardiopulmonary resuscitation (CPR) x 10 minutes
* Acute trauma
* Exsanguination
* Cardiac arrest experienced while in hospital

Primary outcomes:
measure: Successful Conversion to an Organized Heart Rhythm
timeFrame: Termination of defibrillation
Secondary outcomes:
measure: Survival to Hospital Discharge
timeFrame: 30 days
measure: Resuscitation for Survival to One Hour
timeFrame: One hour from termination of defibrillation
measure: Neurologic Function
timeFrame: 30 days
measure: Return of Spontaneous Circulation
timeFrame: Termination of defibrillation
measure: Survival to 24 Hours
timeFrame: 24 hours
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: Ottawa Hospital
state: Ontario
Study officials:
affiliation: OHRI
name: Ian Stiell, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Stiell IG, Walker RG, Nesbitt LP, Chapman FW, Cousineau D, Christenson J, Bradford P, Sookram S, Berringer R, Lank P, Wells GA. BIPHASIC Trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest. Circulation. 2007 Mar 27;115(12):1511-7. doi: 10.1161/CIRCULATIONAHA.106.648204. Epub 2007 Mar 12.
Clinical trial NCT06432192: A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis
Official title: ApoDiag: A Prospective, Monocentric Clinical Study for the Validation of in Vitro Diagnostic Tests Developed by Firalis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Genetic Health Risks
Keywords: Polygenic risk
APOE, Apolipoprotein
Neurodegenerative disorders
Dementia
Alzheimer disease
Genetic risks
Lead sponsor: Firalis SA
Sponsor class: INDUSTRY
First posted: 2024-05-29
Enrollment: 1474
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy donors

Brief summary: Firalis SA and its affiliate Amoneta Diagnostics SAS are developing novel in-vitro-diagnostic (IVD) tests for diverse diagnostic applications for major human diseases, including cardiovascular, and neurodegenerative disorders. These tests detect several gene mutations related to the above-mentioned pathologies. The development of IVD tools requires the evaluation of analytical parameters including biomarker stability.

The present specific study therefore aims to collect whole blood samples in PAXgene DNA tubes to complete the analytical validation of IVD tools and the evaluation of the stability of the DNA in PAXgene DNA tubes and the reagents in the IVD tools.


Eligibility criteria: Inclusion Criteria:

* Donors who sign the informed consent forms for sample collection and for genotyping.
* Adults, both genders, aged 18-85 years.
* Not under any administrative or legal supervision

Exclusion Criteria:

* Anyone who did not sign the Informed Consent form.
* Subjects aged below 18 years and older than 85 years are excluded.
* Pregnant, parturient and nursing women are excluded

Primary outcomes:
measure: APOE Genotype
timeFrame: Baseline
Secondary outcomes:
measure: Specimen stability
timeFrame: Baseline, 24hrs, 5 days, 28 days, 3 months, 12 months, 24 months
Other outcomes:
Locations:
city: Nancy
country: France
facility: EFS GEST
city: Strasbourg
country: France
facility: EFS GEST
Study officials:
affiliation: Firalis SA
name: Huseyin Firat, MD PhD
role: STUDY_DIRECTOR
affiliation: Firalis SA
name: Lucas Pham-Van, PhD
role: STUDY_CHAIR
affiliation: Firalis SA
name: Joanna Michel
role: STUDY_CHAIR
affiliation: Firalis SA
name: Sthepanie Boutillier, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04775992: Preemptive Analgesia of Gabapentoids in Orthopedic Surgery
Official title: Preemptive Analgesia of Gabapentoids After Major Orthopedic Surgery: Systematic Review and Meta Analysis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Postoperative Pain
Keywords: acute postoperative pain
Preemptive analgesia
Orthopedic surgery
Preoperative gabapentoids
Lead sponsor: King Saud University
Sponsor class: OTHER
First posted: 2021-03-01
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: all included RCT

Brief summary: To address the preemptive analgesic effect of preoperative gabapentoids versus no gabapentoids in orthopedic surgery

Detailed description: Computer search for all studies used preoperative gabapentoids versus no gabapentoids in orthopedic surgery during the last 10 years (from 2011 - 2020)

Eligibility criteria: Inclusion Criteria:

* RCT, during last 10 years, involving orthopedic surgery

Exclusion Criteria:

* non randomized trials, unavailable study data

Primary outcomes:
measure: Postoperative pain score on rest
timeFrame: every hour for the first 24 hours
measure: Postoperative pain during movement
timeFrame: every hour for the first 24 hours
Secondary outcomes:
measure: Worst pain score
timeFrame: during the first 24 hours
measure: Least pain score
timeFrame: during the first 24 hours
measure: Time spend in severe pain
timeFrame: during the first 24 hours
measure: Patient's satisfaction
timeFrame: during the first 24 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02383992: Postoperative Care of Sutured Wounds
Official title: Comparing the Efficacy of Hydrogen Peroxide Versus Normal Saline in Postoperative Care of Sutured Wounds
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Wound Healing
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2015-03-10
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to compare the efficacy of hydrogen peroxide versus normal saline in postoperative care of sutured wounds. Subjects will be randomly assigned to standard of care hydrogen peroxide or standard of care normal saline in postoperative care of sutured wounds followed by applying petroleum jelly and sterile gauze bandage. Data will be collected at day 0 and between days 7 to14. Subjects will provide irritation scale rating (0-4) with 0 being none/absent and 4 being severe/extreme.


Eligibility criteria: Inclusion Criteria:

1. Patients who are undergoing sutured wound after dermatologic procedure.
2. Males and females ages 18-65 years old.
3. Patients who are in good health.
4. Willingness and the ability to understand and provide informed consent and communicate with the investigator/study staff.

Exclusion Criteria:

1. History of keloids or hypertrophic scars.
2. History of bleeding tendency or coagulopathy.
3. Pregnant or lactating or intends to become pregnant in the next 3 months.
4. Active skin disease or skin infection in the treatment area.
5. Unable to understand the protocol or to give informed consent.
6. Any other condition that would, in the professional opinion of the investigator, potentially affect response or participation in the clinical clinical study, or would pose as an unacceptable risk to the subject.

Primary outcomes:
measure: Irritation scale rating from 1-2 weeks compared to baseline
timeFrame: Baseline and 1-2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University Feinberg School of Medicine, Department of Dermatology
state: Illinois
Study officials:
affiliation: Northwestern University
name: Murad Alam, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02172092: Fluid Kinetics in Patients With Diabetic Ketoacidosis
Official title: Fluid Kinetics in Patients With Diabetic Ketoacidosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Keywords: Diabetes
Ketoacidosis
fluid shift
Lead sponsor: University Hospital, Linkoeping
Sponsor class: OTHER
Collaborators: name: Vrinnevi Hospital
First posted: 2014-06-24
Enrollment: 17
Sex: ALL
Minimum age (years): 17
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose with the study is to follow the fluid shifts that occur during fluid resuscitation of patients with diabetic ketoacidosis.

In the study measurements of changes in blood and urine concentrations of Sodium and Chloride as well as blood hemoglobin are used to mathematically calculate changes in distribution volumes of these different endogenous markers.

Detailed description: Patients treated for diabetic ketoacidosis receive 1000 ml of Sodium Chloride during the first 30 minutes of treatment.

Before, during and after this infusion regular blood samples(and urine) are collected (0, 10, 20, 30, 35, 40, 45, 50, 60, 120, 180 and 300 minutes after infusion start).

B-Hemoglobin, P-Albumine, B-Glucose, P-Sodium, P-Potassium. P-Chlorides, U-Sodium, U-Chloride and U-Glucose. Hourly volume of urine is measured.

The 30 minute infusion can be used to calculate the urine extracellular volume. Thereafter during infusion of Ringers acetate changes in electrolytes in blood as well as urine volume and in the urine excreted electrolytes can be used to calculate the fluid shifts between the different fluid compartments.

Eventually 8 to 12 hours later a second infusion of SodiumChloride is as a control performed.

Eligibility criteria: Inclusion Criteria:

* diabetic ketoacidosis needing icu care, conscious patient, signed informed consent.

Exclusion Criteria:

* unconscious patient

Primary outcomes:
measure: Extracellular volume
timeFrame: 120 minutes
Secondary outcomes:
measure: Distribution of strong and weak acids
timeFrame: 12 hours
Other outcomes:
Locations:
city: Norrköping
country: Sweden
facility: Vrinnevi Hospital
state: Östergötland
Study officials:
affiliation: Linkoeping University
name: Robert Hahn, Prof
role: STUDY_DIRECTOR
References:
citation: Svensson R, Hahn RG, Zdolsek JH, Bahlmann H. Plasma volume expansion reveals hidden metabolic acidosis in patients with diabetic ketoacidosis. Intensive Care Med Exp. 2022 Dec;10(1):36. doi: 10.1186/s40635-022-00464-5. Epub 2022 Aug 29.
Clinical trial NCT05091892: Hydrotherapy CP and Lying Down to Sitting Position
Official title: The Effect of a Specific Hydrotherapy Program on the Movement From Lying Down to Sitting Position for Children With Cerebral Palsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebral Palsy
Keywords: Cerebral palsy
hydrotherapy
Neurodevelopmental treatment
Lying down
Sitting
Lead sponsor: University of Thessaly
Sponsor class: OTHER
First posted: 2021-10-25
Enrollment: 40
Sex: ALL
Minimum age (years): 5
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 2 equal groups
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to investigate the effect of a very specific hydrotherapy programm on the movement from lying down to sitting position for children with CP

Detailed description: 40 children aged 5-11 years with cerebral palsy and difficulty in the transfer activity from lying down to sitting position were randomly divided into 2 groups of 20 children, a land group and a water group. The children of the land attended a neurodevelopmental treatment program and the water group a very specific program in hydrotherapy on combined rotation at all levels. The water program was implemented by specialized physiotherapists in hydrotherapy. The duration of the program for both groups was 3 months. On the first and last day of the intervention, an evaluation of all children was performed using the GMFM and PBS evaluation tests of the evaluation parameters of the transfer from the lying position to the sitting position.

Eligibility criteria: Inclusion Criteria:

* Cerebral palsy
* DIfficulties from lying down to sitting posistion

Exclusion Criteria:

* Surgery or injection of botilium toxin in the last year.
* Scheduled surgery or injection of botilium toxin.
* Uncontrolled seizures.
* Do not run elementary commands or play a test representation.
* Autism.
* Syndromes without OP.
* Serious vision problem.
* Absence from the treatment program for more than a week.

Primary outcomes:
measure: GMFM
timeFrame: 3 months
measure: PBS
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Konstantinos Chandolias
Study officials:
References:
Clinical trial NCT01380392: The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma
Official title: The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Liver Carcinoma
Keywords: Liver cancer
Uncertainty
Personality
coping strategies
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2011-06-27
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HCC patients who accept surgical or medical treatment.

Brief summary: The aims of this study are to (1) understand the uncertainty , personality and coping strategies in patients with HCC, and identify the significant factors for coping.

Detailed description: A cross-sectional correlated design will be used and (2) patients will be recruited by purposive sampling from wards and outpatient departments at a medical center in Taipei.

Eligibility criteria: Inclusion Criteria:

* Adult
* Has HCC and knows condition
* Con's clear
* Agree join the study

Exclusion Criteria:e

* BCLC stage C or D
* Accepted C/T, R/T,target therapy or supportive care
* Patient who receive liver transplantation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Research Nurse
Study officials:
affiliation: National Taiwan University
name: Shiow-Ching Shun, Doctor
role: STUDY_CHAIR
References: